IL17A and spondyloarthropathy: A growing body of evidence suggests that upregulation of the IL-23/IL-17 axis in PsA and axSpA patients may be a key factor in the metabolic-related inflammatory profile, explaining the high prevalence of cardiometabolic comorbidities among spondyloarthritis patients.